Prediction of alpha-blocker response in men with benign prostatic hyperplasia by magnetic resonance imaging

Author： Mimata H. Nomura Y. Kasagi Y. Satoh F. Emoto A. Li W. Douno S. Mori H.

Publisher： Elsevier

ISSN： 0090-4295

Source： Urology, Vol.54, Iss.5, 1999-11, pp. : 829-833

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Alpha-blockade: monotherapy for hypertension and benign prostatic hyperplasia

By Kaplan S.A. Kaplan N.M.

Urology, Vol. 48, Iss. 4, 1996-10 ,pp. : 541-550

Elsevier

Access to resources Recommend Favorite

Benign prostatic hyperplasia: a progressive disease of aging men

By Emberton M. Andriole G.L. de la Rosette J. Djavan B. Hoefner K. Vela Navarrete R. Nordling J. Roehrborn C. Schulman C. Teillac P. Tubaro A. Nickel J.C.

Urology, Vol. 61, Iss. 2, 2003-02 ,pp. : 267-273

Elsevier

Access to resources Recommend Favorite

Comparison of a phytotherapeutic agent (permixon) with an alphablocker. (Tamsulosin) in the treatment of benign prostatic hyperplasia: a 1-year randomised international study

By Debruyne F.

European Urology Supplements, Vol. 1, Iss. 1, 2002-01 ,pp. : 108-108

Elsevier

Access to resources Recommend Favorite

Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia

By Roehrborn C.G. Boyle P. Nickel J.C. Hoefner K. Andriole G. the ARIA3001 ARIA3002 and ARIA3003 Study Investigators

Urology, Vol. 60, Iss. 3, 2002-09 ,pp. : 434-441

Elsevier

Access to resources Recommend Favorite

Discontinuation of alpha-blockade after initial treatment with finasteride and doxazosin in men with lower urinary tract symptoms and clinical evidence of benign prostatic hyperplasia

By Baldwin K.C. Ginsberg P.C. Roehrborn C.G. Harkaway R.C.

Urology, Vol. 58, Iss. 2, 2001-08 ,pp. : 203-208

Elsevier

Access to resources Recommend Favorite